MedTrace Logo

Lung Cancer Risk in Type 2 Diabetes With COPD: SGLT2 Inhibitors vs. Sulfonylureas

NCT07332156 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 21692

Last updated 2026-01-14

No results posted yet for this study

Summary

The goal of this observational study is to learn if a specific diabetes medicine can lower the risk of lung cancer in people with type 2 diabetes and chronic obstructive pulmonary disease (COPD).

The main question it aims to answer is:

\- Does taking medicines called SGLT2 inhibitors lower the chance of getting lung cancer compared to medicines called sulfonylureas?

Researchers will compare the medical records of people taking SGLT2 inhibitors to those taking sulfonylureas to see if the SGLT2 group has fewer cases of lung cancer.

Participants will not need to visit a doctor or take new medicines for this study. Researchers will use information from existing medical records to answer the research question.

Conditions

  • Type 2 Diabetes
  • COPD (Chronic Obstructive Pulmonary Disease)
  • Lung Cancer (Diagnosis)

Interventions

DRUG

SGLT2 inhibitor

Any new prescription of SGLT2 inhibitors after new onset of T2DM

DRUG

Sulfonylureas (SU)

Any new prescription of sulfonylureas after new onset of T2DM

DRUG

DPP4 inhibitors

Any new prescription of DPP4 inhibitors after new onset of T2DM

Sponsors & Collaborators

  • Samsung Medical Center

    lead OTHER

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-01
Primary Completion
2023-12-31
Completion
2023-12-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07332156 on ClinicalTrials.gov